Cargando…

Identification of key clinical phenotypes of breast cancer using a reduced panel of protein biomarkers

BACKGROUND: Breast cancer is a heterogeneous disease characterised by complex molecular alterations underlying the varied behaviour and response to therapy. However, translation of cancer genetic profiling for use in routine clinical practice remains elusive or prohibitively expensive. As an alterna...

Descripción completa

Detalles Bibliográficos
Autores principales:	Green, A R, Powe, D G, Rakha, E A, Soria, D, Lemetre, C, Nolan, C C, Barros, F F T, Macmillan, R D, Garibaldi, J M, Ball, G R, Ellis, I O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3790179/ https://www.ncbi.nlm.nih.gov/pubmed/24008658 http://dx.doi.org/10.1038/bjc.2013.528

Ejemplares similares

Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer
por: Rakha, E A, et al.
Publicado: (2014)

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

KPNA2 is a nuclear export protein that contributes to aberrant localisation of key proteins and poor prognosis of breast cancer
por: Alshareeda, A T, et al.
Publicado: (2015)

MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours
por: Green, Andrew R, et al.
Publicado: (2016)

Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype
por: Elsheikh, S E, et al.
Publicado: (2008)

KI67 and DLX2 predict increased risk of metastasis formation in prostate cancer–a targeted molecular approach
por: Green, William JF, et al.
Publicado: (2016)

Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy response
por: Al-kaabi, M M, et al.
Publicado: (2015)

Identification and definition of novel clinical phenotypes of breast cancer through consensus derived from automated clustering methods
por: Green, AR, et al.
Publicado: (2008)

Absence of p300 induces cellular phenotypic changes characteristic of epithelial to mesenchyme transition
por: Krubasik, D, et al.
Publicado: (2006)

Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers
por: Klimov, Sergey, et al.
Publicado: (2017)

Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
por: Dingli, D, et al.
Publicado: (2009)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype
por: Grelier, G, et al.
Publicado: (2009)

Endogenous myoglobin in human breast cancer is a hallmark of luminal cancer phenotype
por: Kristiansen, G, et al.
Publicado: (2010)

Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs
por: Brookes, K, et al.
Publicado: (2010)

Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53
por: Millar, E K A, et al.
Publicado: (2011)

Prognostic significance of vascular endothelial cell growth factors -A, -C and -D in breast cancer and their relationship with angio- and lymphangiogenesis
por: Mohammed, R A A, et al.
Publicado: (2007)

ERK5 signalling in prostate cancer promotes an invasive phenotype
por: Ramsay, A K, et al.
Publicado: (2011)

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues
por: Riddick, A C P, et al.
Publicado: (2005)

Evaluation of a new panel of six mononucleotide repeat markers for the detection of DNA mismatch repair-deficient tumours
por: Pagin, A, et al.
Publicado: (2013)

Serum microRNA panel as biomarkers for early diagnosis of colorectal adenocarcinoma
por: Zheng, G, et al.
Publicado: (2014)

Rho-GTPase activating-protein 18: a biomarker associated with good prognosis in invasive breast cancer
por: Aleskandarany, Mohammed A, et al.
Publicado: (2017)

Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer
por: Green, Andrew R., et al.
Publicado: (2016)

Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines
por: Beesley, A H, et al.
Publicado: (2006)

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
por: Dawson, S-J, et al.
Publicado: (2010)

Primary breast cancer stem-like cells metastasise to bone, switch phenotype and acquire a bone tropism signature
por: D′Amico, L, et al.
Publicado: (2013)

Serum biomarker panels for the diagnosis of gastric adenocarcinoma
por: Ahn, H S, et al.
Publicado: (2012)

Prediction of ovarian cancer prognosis and response to chemotherapy by a serum-based multiparametric biomarker panel
por: Oikonomopoulou, K, et al.
Publicado: (2008)

Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study
por: Aparicio, T, et al.
Publicado: (2013)

Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer
por: Korbakis, D, et al.
Publicado: (2015)

A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer
por: Zhu, C, et al.
Publicado: (2014)

The expression of p53-induced protein with death domain (Pidd) and apoptosis in oral squamous cell carcinoma
por: Bradley, G, et al.
Publicado: (2007)

Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype
por: Ameri, K, et al.
Publicado: (2010)

Analysis of a panel of antibodies to APC reveals consistent activity towards an unidentified protein
por: Davies, M L, et al.
Publicado: (2007)

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
por: Farace, F, et al.
Publicado: (2011)

Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours
por: Weidlich, S, et al.
Publicado: (2011)

TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer
por: Knight, J F, et al.
Publicado: (2008)

Neuroendocrine and epithelial phenotypes in small-cell lung cancer: implications for metastasis and survival in patients
por: Stovold, R, et al.
Publicado: (2013)

A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer Screening in Rotterdam, Netherlands
por: Gupta, A, et al.
Publicado: (2010)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_pe98ci5v2p1vt0cup187mhpsoc